New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc.("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether Ocugen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 12, 2021, Ocugen issued a press release announcing the cancelation of a Company stockholder meeting previously scheduled for January 13, 2021, the following day. The press release stated that "[t]he Company plans to reevaluate the details of" a proposed share increase "in light of the recent potential addition of COVAXINT to its pipeline as well as its compliance with Nasdaq's Listing Rule 5550(a)(2)."
On this news, Ocugen's stock price fell $0.26 per share, or 10.44%, to close at $2.23 per share on January 12, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72504